Long GV, et al. - This study was designed to report 5-year efficacy and safety outcomes in patients with BRAF V600–mutant metastatic melanoma (MM) who received =BRAF inhibitor (dabrafenib [D]) and MEK inhibitor (trametinib [T]) combination therapy versus D monotherapy in the randomized phase II BRF113220 study part C. Findings from this 5-year analysis, which represents the longest follow-up to date, demonstrated that BRAF + MEK inhibitor combination therapy elicited durable plateaus of long-term overall survival and progression-free survival that lasted ≥ 5 years in some patients with MM. These findings were consistent with trends observed in landmark analyses with shorter follow-up.